Arrowhead Pharmaceuticals (ARWR) ROIC: History & Chart

Name: Arrowhead Pharmaceuticals, Inc. (ARWR) Return on Invested Capital (ROIC) — historical time series
Creator: TGMCharts

Compare

Arrowhead Pharmaceuticals, Inc.(ARWR)

Biotechnology · Pasadena, CA

$62.35-1.84 (-2.87%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

Compare

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Pasadena, CA

711 employees

arrowheadpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher R. Anzalone

View full financials

ARWR Return on Invested Capital (ROIC) Metrics

RETURN ON INVESTED CAPITAL (ROIC)

-12.12%

RETURN ON INVESTED CAPITAL (ROIC) AVG TTM

-1.19%

RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y

-28.42%

RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y

-27.41%

RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y

-27.77%

RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y

-39.33%

RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y

-56.78%

CURRENT VS TTM AVG

-919.51%

CURRENT VS 3Y AVG

+57.37%

CURRENT VS 5Y AVG

+55.78%

CURRENT VS 10Y AVG

+56.36%

CURRENT VS 15Y AVG

+69.19%

CURRENT VS 20Y AVG

+78.66%

SECTOR MEDIAN · HEALTHCARE

-27.19%

median of 428 covered companies

CURRENT VS SECTOR MEDIAN

+55.43%

vs the sector median at left

NAME	MARKET CAP	RETURN ON INVESTED CAPITAL (ROIC)	TTM	3Y	5Y
Arrowhead Pharmaceuticals, Inc. (ARWR)	$8.78B	-12.12%	-1.19%	-28.42%	-27.41%
Caris Life Sciences, Inc. (CAI)vs ›	$8.59B	14.76%	-51.69%	-63.43%	-49.69%
Axsome Therapeutics, Inc. (AXSM)vs ›	$9.11B	-50.82%	-63.49%	-63.78%	-84.79%
Oscar Health, Inc. (OSCR)vs ›	$8.41B	22.98%	-12.21%	-17.44%	-20.18%
Bruker Corporation (BRKRP)vs ›	$9.35B	2.56%	2.83%	6.99%	7.71%
Insulet Corp. (PODD)vs ›	$9.39B	16.04%	12.65%	9.01%	7.29%
Henry Schein, Inc. (HSIC)vs ›	$9.60B	6.53%	6.69%	7.80%	8.31%
Bruker Corporation (BRKR)vs ›	$9.72B	2.56%	2.83%	6.99%	7.71%
Cytokinetics, Incorporated (CYTK)vs ›	$7.80B	-39.80%	-45.97%	-48.64%	-39.58%
HealthEquity, Inc. (HQY)vs ›	$7.65B	8.55%	6.73%	4.46%	3.72%

NAME

MARKET CAP

RETURN ON INVESTED CAPITAL (ROIC)

TTM

Arrowhead Pharmaceuticals, Inc. (ARWR)

$8.78B

-12.12%

-1.19%

-28.42%

-27.41%

Caris Life Sciences, Inc. (CAI)vs ›

$8.59B

14.76%

-51.69%

-63.43%

-49.69%

Axsome Therapeutics, Inc. (AXSM)vs ›

$9.11B

-50.82%

-63.49%

-63.78%

-84.79%

Oscar Health, Inc. (OSCR)vs ›

$8.41B

22.98%

-12.21%

-17.44%

-20.18%

Bruker Corporation (BRKRP)vs ›

$9.35B

2.56%

2.83%

6.99%

7.71%

Insulet Corp. (PODD)vs ›

$9.39B

16.04%

12.65%

9.01%

7.29%

Henry Schein, Inc. (HSIC)vs ›

$9.60B

6.53%

6.69%

7.80%

8.31%

Bruker Corporation (BRKR)vs ›

$9.72B

2.56%

2.83%

6.99%

7.71%

Cytokinetics, Incorporated (CYTK)vs ›

$7.80B

-39.80%

-45.97%

-48.64%

-39.58%

HealthEquity, Inc. (HQY)vs ›

$7.65B

8.55%

6.73%

4.46%

3.72%

Return on Invested Capital (ROIC) Formula & Definition

ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)

Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.

Return on Invested Capital (ROIC) FAQ

What is the return on invested capital (ROIC) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The return on invested capital (ROIC) for ARWR stock is -12.12%.

Is Arrowhead Pharmaceuticals, Inc.'s return on invested capital (ROIC) high or low?

The return on invested capital (ROIC) of -12.12% is 56% above its 5-year average of -27.41%, around the middle of its 5-year range (-69.00%–21.24%).

What is the TTM average return on invested capital (ROIC) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The TTM average return on invested capital (ROIC) for ARWR stock is -1.19%.

What is the 3Y average return on invested capital (ROIC) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 3Y average return on invested capital (ROIC) for ARWR stock is -28.42%.

What is the 5Y average return on invested capital (ROIC) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 5Y average return on invested capital (ROIC) for ARWR stock is -27.41%.

What is the 10Y average return on invested capital (ROIC) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 10Y average return on invested capital (ROIC) for ARWR stock is -27.77%.

What is the 15Y average return on invested capital (ROIC) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 15Y average return on invested capital (ROIC) for ARWR stock is -39.33%.

What is the 20Y average return on invested capital (ROIC) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 20Y average return on invested capital (ROIC) for ARWR stock is -56.78%.

DATE	RETURN ON INVESTED CAPITAL (ROIC)
2026-06-30	-12.12%
2026-03-31	-10.98%
2025-12-31	21.24%
2025-09-30	4.67%
2025-06-30	-8.76%
2025-03-31	-8.32%
2024-12-31	-67.44%
2024-09-30	-57.63%
2024-06-30	-69.00%
2024-03-31	-52.92%
2023-12-31	-52.90%
2023-09-30	-30.57%
2023-06-30	-24.78%
2023-03-31	-18.68%
2022-12-31	-20.37%
2022-09-30	-32.11%
2022-06-30	-25.47%
2022-03-31	-20.88%
2021-12-31	-37.34%
2021-09-30	-26.34%
2021-06-30	-24.83%
2021-03-31	-20.03%
2020-12-31	-23.64%
2020-09-30	-19.29%
2020-06-30	-6.50%
2020-03-31	0.22%
2019-12-31	8.80%
2019-09-30	24.15%
2019-06-30	16.17%
2019-03-31	2.53%
2018-12-31	-15.11%
2018-09-30	-56.23%
2018-06-30	-51.91%
2018-03-31	-37.95%
2017-12-31	-48.06%
2017-09-30	-43.26%
2017-06-30	-51.11%
2017-03-31	-62.47%
2016-12-31	-71.94%
2016-09-30	-79.57%
2016-06-30	-120.24%
2016-03-31	-101.59%
2015-12-31	-91.06%
2015-09-30	-82.47%
2015-06-30	-68.63%
2015-03-31	-60.20%
2014-12-31	-47.39%
2014-09-30	-31.15%
2014-06-30	-20.66%
2014-03-31	-16.88%
2013-12-31	-31.62%
2013-09-30	-83.14%
2013-06-30	-61.47%
2013-03-31	-364.79%
2012-12-31	-216.68%
2012-09-30	-186.63%
2012-06-30	-174.50%
2012-03-31	-99.16%
2011-12-31	-58.51%
2011-09-30	-73.88%
2011-06-30	-83.25%
2011-03-31	-69.75%
2010-12-31	-108.79%
2010-09-30	-85.06%
2010-06-30	-85.00%
2010-03-31	-156.82%
2009-12-31	-186.87%
2009-09-30	-365.61%
2009-06-30	-577.05%
2009-03-31	-615.95%
2008-12-31	-326.71%
2008-09-30	-246.96%
2008-06-30	-214.21%
2008-03-31	-173.10%
2007-12-31	-142.21%
2007-09-30	-140.78%
2007-06-30	-103.82%
2007-03-31	-101.69%
2006-12-31	-70.97%
2006-09-30	-73.81%
2006-06-30	-42.80%
2006-03-31	-35.09%
2005-12-31	-43.59%
2005-09-30	-29.31%
2005-06-30	-25.74%
2005-03-31	-38.91%
2004-12-31	-44.50%
2004-09-30	-24.66%
2004-06-30	-10.93%
2004-03-31	-6.16%
2003-12-31	-9.71%
2003-09-30	-6.65%

DATE

RETURN ON INVESTED CAPITAL (ROIC)

2026-06-30

-12.12%

2026-03-31

-10.98%

2025-12-31

21.24%

2025-09-30

4.67%

2025-06-30

-8.76%

2025-03-31

-8.32%

2024-12-31

-67.44%

2024-09-30

-57.63%

2024-06-30

-69.00%

2024-03-31

-52.92%

2023-12-31

-52.90%

2023-09-30

-30.57%

2023-06-30

-24.78%

2023-03-31

-18.68%

2022-12-31

-20.37%

2022-09-30

-32.11%

2022-06-30

-25.47%

2022-03-31

-20.88%

2021-12-31

-37.34%

2021-09-30

-26.34%

2021-06-30

-24.83%

2021-03-31

-20.03%

2020-12-31

-23.64%

2020-09-30

-19.29%

2020-06-30

-6.50%

2020-03-31

0.22%

2019-12-31

8.80%

2019-09-30

24.15%

2019-06-30

16.17%

2019-03-31

2.53%

2018-12-31

-15.11%

2018-09-30

-56.23%

2018-06-30

-51.91%

2018-03-31

-37.95%

2017-12-31

-48.06%

2017-09-30

-43.26%

2017-06-30

-51.11%

2017-03-31

-62.47%

2016-12-31

-71.94%

2016-09-30

-79.57%

2016-06-30

-120.24%

2016-03-31

-101.59%

2015-12-31

-91.06%

2015-09-30

-82.47%

2015-06-30

-68.63%

2015-03-31

-60.20%

2014-12-31

-47.39%

2014-09-30

-31.15%

2014-06-30

-20.66%

2014-03-31

-16.88%

2013-12-31

-31.62%

2013-09-30

-83.14%

2013-06-30

-61.47%

2013-03-31

-364.79%

2012-12-31

-216.68%

2012-09-30

-186.63%

2012-06-30

-174.50%

2012-03-31

-99.16%

2011-12-31

-58.51%

2011-09-30

-73.88%

2011-06-30

-83.25%

2011-03-31

-69.75%

2010-12-31

-108.79%

2010-09-30

-85.06%

2010-06-30

-85.00%

2010-03-31

-156.82%

2009-12-31

-186.87%

2009-09-30

-365.61%

2009-06-30

-577.05%

2009-03-31

-615.95%

2008-12-31

-326.71%

2008-09-30

-246.96%

2008-06-30

-214.21%

2008-03-31

-173.10%

2007-12-31

-142.21%

2007-09-30

-140.78%

2007-06-30

-103.82%

2007-03-31

-101.69%

2006-12-31

-70.97%

2006-09-30

-73.81%

2006-06-30

-42.80%

2006-03-31

-35.09%

2005-12-31

-43.59%

2005-09-30

-29.31%

2005-06-30

-25.74%

2005-03-31

-38.91%

2004-12-31

-44.50%

2004-09-30

-24.66%

2004-06-30

-10.93%

2004-03-31

-6.16%

2003-12-31

-9.71%

2003-09-30

-6.65%

Return on Invested Capital (ROIC): -12.12%

ARWR Return on Invested Capital (ROIC)

ARWR Average Return on Invested Capital (ROIC) Chart

ARWR Current vs Average Return on Invested Capital (ROIC) Chart

ARWR Return on Invested Capital (ROIC) Metrics

ARWR Competitors' Return on Invested Capital (ROIC)

Capital Efficiency

Return on Invested Capital (ROIC) Formula & Definition

Return on Invested Capital (ROIC) FAQ

ARWR Return on Invested Capital (ROIC) History

Related Metrics